Now available from Rules-Based Medicine
Alamar NULISA™ panels – Exceptional multiplexing without compromising sensitivity
Panels available for inflammation and CNS biomarkers
Rules-Based Medicine (RBM) is proud to introduce Alamar NULISA™ panels, a breakthrough in ultra-sensitive biomarker detection for inflammation and central nervous system (CNS) research. NULISA delivers exceptional multiplexing without compromising sensitivity, making it an ideal platform for low abundance biomarkers.
Commercial panels are available now! Click the link below to get a quote on these panels or to inquire about panels or custom assay development.
NULISA™ Assay Capabilities
Alamar’s nucleic acid-linked immuno-sandwich assay – NULISA – technology provides exceptional performance characteristics*:
- Detects low-abundance proteins – attomolar levels (fg/mL) – which can be critical for mechanism-of-action studies
- Analyzes hundreds of biomarkers from a single low-volume sample without loss of sensitivity, enabling comprehensive biomarker profiling
- Demonstrates exceptional reproducibility across runs and plates, with a CV (coefficient of variation) <10%
- Measures both low-abundance biomarkers and high-abundance biomarkers in the same panel using a ~12-log dynamic range
- Delivers reliable, reproducible results for clinical and translational research
*performance characteristics determined by Alamar
Why Rules-Based Medicine?
- Decades of expertise in biomarker development, and validation
- SOP workflows for consistent, high-quality data
- Documented quality processes, including IQ/OQ/PQ and concordance testing
- Custom assay development capabilities on various platforms
- Ability to test on multiple platforms
NULISAseq Inflammation Panel AQ
(absolute quantification for 150 biomarkers)
- Detects biomarkers across 250 targets
- Provides quantitative measurements for 150 inflammatory biomarkers – including cytokines, chemokines and growth factors – involved in key biological processes
- Includes biomarkers with clinical utility in developing biosignatures for early detection, disease progression and measuring therapeutic response
- Enables deeper understanding of inflammatory processes critical to understanding therapeutic efficacy and safety
- Demonstrates clinical utility in a variety of inflammatory and autoimmune conditions, such as lupus, rheumatoid arthritis, vasculitis and inflammatory bowel disease
- Ideal for tracking changes in key proteins over time, supporting:
- Pharmacodynamic studies – assessing drug effects on biological system
- Comparing cohorts of diseased samples to healthy normal volunteers
- Longitudinal and population health studies
-
Download an Excel file of Inflammation AQ analytes
NULISAseq Inflammation Panel 250
- Broad coverage to analyze 250 inflammatory biomarkers, including cytokines, chemokines and inflammatory mediators
- Includes a number of low-abundance biomarkers, enabling detection of biomarkers that other technologies may miss
- Gain insights into early disease biosignatures in inflammatory conditions such as autoimmune diseases, neuroinflammatory conditions and immuno-oncology
-
Download an Excel file of Inflammation 250 analytes
NULISAseq CNS Disease Panel 120
-
Detects 120 proteins from minimal sample volumes (25 µL sample input)
-
Detects analytes with utility in discriminating between neurodegenerative conditions, including amyloid betas, pTaus and synucleins
-
Attomolar sensitivity enables detection of low-abundance biomarkers that are not well suited to traditional platforms or technologies
-
Ideal for identifying and understanding complex pathways involved in neurodegenerative and neuroinflammatory conditions, such as Alzheimer’s, Parkinson’s and multiple sclerosis. These biomarkers can be critical in evaluating new therapeutics for neurodegenerative conditions.
-
Download an Excel file of CNS 120 analytes
